CURE - Direxion Daily Healthcare Bull 3x Shares
| Assets | $154.49M |
| NAV | $93.63 |
| Expense Ratio | 1.08% |
| PE Ratio | 24.41 |
| Beta (5Y) | 2.44 |
| Dividend (ttm) | $0.03 |
| Dividend Yield | 0.03% |
| Ex-Dividend Date | Dec 22, 2020 |
| 1-Year Return | - |
| Trading Day | April 20 |
| Last Price | $94.90 |
| Previous Close | $93.67 |
| Change ($) | 1.23 |
| Change (%) | 1.31% |
| Day's Open | 92.85 |
| Day's Range | 92.45 - 95.52 |
| Day's Volume | 109,325 |
| 52-Week Range | 46.83 - 95.52 |
Fund Description
The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the Health Care Select Sector Index. The fund invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index and other financial instruments that provide daily leveraged exposure to the index or to ETFs that track the index. The index includes domestic companies from the healthcare sector, which includes: pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and etc. It is non-diversified.
| Asset Class Equity | Sector Healthcare |
| Region North America | Inception Date Jun 15, 2011 |
| Exchange NYSEARCA | Ticker Symbol CURE |
| Index Tracked Health Care Select Sector Index | |
Top 10 Holdings
85.87% of assets| Name | Symbol | Weight |
|---|---|---|
| HEALTH CARE SELECT SECTOR INDEX SWAP | n/a | 25.79% |
| HEALTH CARE SELECT SECTOR INDEX SWAP | n/a | 18.79% |
| HEALTH CARE SELECT SECTOR INDEX SWAP | n/a | 15.21% |
| Health Care Select Sector Index SWAP | n/a | 12.27% |
| BANK OF NEW YORK CASH RESERVE | n/a | 4.23% |
| GOLDMAN FS GOVT INST | n/a | 2.94% |
| DREYFUS GOVT CASH MGMT | n/a | 2.84% |
| Johnson & Johnson | JNJ | 1.53% |
| UnitedHealth | UNH | 1.33% |
| GOLDMAN FINL SQ TRSRY INST 506 | n/a | 0.94% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 22, 2020 | $0.006 | Dec 30, 2020 |
| Sep 22, 2020 | $0.01 | Sep 29, 2020 |
| Jun 23, 2020 | $0.016 | Jun 30, 2020 |
| Mar 24, 2020 | $0.10 | Mar 31, 2020 |
| Dec 23, 2019 | $0.00 | Dec 31, 2019 |
| Sep 24, 2019 | $0.203 | Oct 1, 2019 |
U.S. president Joe Biden's infrastructure plan is opening up ETF trading possibilities from multiple angles. One way is playing its healthcare component via funds like the Direxion Daily Healthcare Bull...
Coronavirus vaccines are being distributed, but case counts continue rising, a pair of scenarios ensuring the healthcare center will again be an epicenter of activity in 2021. What Happened Healthcare i...
The healthcare sector is shaking off rust accrued earlier this year and with the 2020 election season mostly behind the group – pending next month's Georgia Senate runoff elections – market observers ar...
For the better part of 2020, the market has been ruled less by hard numbers and more by speculation about what the hard numbers may look like once the pandemic is “over” and things get back to “normal.”...
Last week was moderately upbeat for Wall Street with vaccine hopes boosting the risk-on sentiments.
Last week witnessed a tug-of-war between bulls and bears.
It has the potential to be lost in this week's earnings hubbub, which is dominated by growth-ier communication services and technology stocks, but don't sleep on reports from blue-chip healthcare stocks.
The coronavirus pandemic put healthcare exchange-traded funds (ETFs) in the forefront as medical providers are an essential component in the global market landscape. However, investors shouldn’t suck up...
These leveraged ETFs won last week despite a broader market bloodbath.
The new coronavirus from China has claimed more than 800 lives and there are now more than 37,000 documented cases of the respiratory illness worldwide, making it more deadly than the 2003 SARS epidemic.
Inside the top-and-worst-performing leveraged ETFs of last week.
Inside the best five best leveraged ETFs of November.
Jablonski: Biotech presents a good buying opportunity
Sylvia Jablonski of Direxion discusses why biotech stocks and ETFs are attractive right now, due to their cheapness relative to the rest of the market.
For traders using leveraged sector exchange-traded funds, one key to successfully using these products in the short-term fashion in which they are intended is to treat leveraged ETFs as event-driven tra...